Trial Results Search
Clinical Trial Results: Non-Small Cell Lung Cancer
-
Protocol Number: BO18279
Product Name: Tarceva [erlotinib]
Date of Report: 01.03.2008
Phase: II
A phase II marker identification trial for erlotinib (Tarceva) in second line NSCLC patients
-
Protocol Number: MO17426
Product Name: Tarceva [erlotinib]
Date of Report: 29.05.2008
Phase: II
-
Protocol Number: BO19734
Product Name: Avastin [bevacizumab]
Date of Report: 04.08.2008
Phase: II
-
Protocol Number: BO18192
Product Name: erlotinib [Tarceva] [erlotinib]
Date of Report: 01.06.2012
Phase: III
-
Protocol Number: BP18193
Product Name: Tarceva [erlotinib [Tarceva]]
Date of Report: 01.10.2007
Phase: I
A phase 1B study of erlotinib (Tarceva) in combination with pemetrexed (Alimta) in NSCLC.
-
Protocol Number: BO20571
Product Name: erlotinib [Tarceva] [erlotinib]
Date of Report: 01.05.2012
Phase: II
-
Protocol Number: BO17704
Product Name: Avastin [bevacizumab]
Date of Report: 01.06.2007
Phase: III
-
Protocol Number: BO21015
Product Name: Avastin [bevacizumab [Avastin]]
Date of Report: 01.07.2011
Phase: II
-
Protocol Number: ML20063
Product Name: erlotinib [Tarceva] [erlotinib]
Date of Report: 01.12.2009
Phase: II
-
Protocol Number: ML22429
Product Name: erlotinib [Tarceva] [erlotinib]
Date of Report: 07.06.2012
Phase: II
-
Protocol Number: BO21247
Product Name: Avastin [bevacizumab [Avastin]]
Date of Report: 01.07.2011
Phase: I
-
Protocol Number: BO21563
Product Name: Avastin [bevacizumab [Avastin]]
Date of Report: 07.07.2010
Phase: I
-
Protocol Number: TOC4603g
Product Name: Tarceva [erlotinib]
Date of Report: To be Published
Phase: II
-
Protocol Number: ML20081
Product Name: bevacizumab [Avastin] [bevacizumab]
Date of Report: 01.02.2010
Phase: II
-
Protocol Number: ML21868
Product Name: Avastin [bevacizumab]
Date of Report: To be Published
Phase: II
-
Protocol Number: MO22097
Product Name: Avastin [bevacizumab]
Date of Report: To be Published
Phase: III
-
Protocol Number: ML21823
Product Name: Avastin [bevacizumab]
Date of Report: To be Published
Phase: II
-
Protocol Number: YO25404
Product Name: Avastin [bevacizumab]
Date of Report: To be Published
Phase: III
-
Protocol Number: NO17352
Product Name: Epothilone D
Date of Report: To be Published
Phase: II
A Study of Epothilone D in Patients With Non-Small Cell Lung Cancer (NSCLC)
-
Protocol Number: ML21869
Product Name: Tarceva [erlotinib]
Date of Report: To be Published
Phase: II
-
Protocol Number: ML20951
Product Name: erlotinib
Date of Report: To be Published
Phase: II
-
Protocol Number: BO25460
Product Name: Tarceva [erlotinib]
Date of Report: To be Published
Phase: III
-
Protocol Number: ML20829
Product Name: erlotinib
Date of Report: To be Published
Phase: II
A Study of Management of Tarceva - Induced Rash in Patients With Non-Small Cell Lung Cancer.
-
Protocol Number: GO28625
Product Name: MPDL3280A
Date of Report: To be Published
Phase: II
-
Protocol Number: GO27821
Product Name: RO5490258
Date of Report: To be Published
Phase: II
-
Protocol Number: OAM4971g
Product Name: onartuzumab
Date of Report: To be Published
Phase: III
-
Protocol Number: GO27820
Product Name: onartuzumab
Date of Report: To be Published
Phase: II
-
Protocol Number: BP22349
Product Name: RO5083945
Date of Report: To be Published
Phase: II
-
Protocol Number: BP28577
Product Name: RO5083945
Date of Report: To be Published
Phase: I
-
Protocol Number: NP28673
Product Name: RO5452802
Date of Report: To be Published
Phase: II
-
Protocol Number: ML25637
Product Name: Tarceva [erlotinib]
Date of Report: To be Published
Phase: II
-
Protocol Number: MO18633
Product Name: erlotinib
Date of Report: To be Published
Phase: II
-
Protocol Number: ML20322
Product Name: erlotinib
Date of Report: To be Published
Phase: IV
A Study of Tarceva (Erlotinib) in Elderly Patients With Advanced Non-Small Cell Lung Cancer
-
Protocol Number: ML27880
Product Name: Tarceva [erlotinib]
Date of Report: To be Published
Phase: IV
-
Protocol Number: ML22606
Product Name: ERLOTINIB
Date of Report: To be Published
Phase: II
-
Protocol Number: MO18660
Product Name: erlotinib
Date of Report: To be Published
Phase: II
-
Protocol Number: ML25514
Product Name: Tarceva [erlotinib]
Date of Report: To be Published
Phase: II
-
Protocol Number: ML25478
Product Name: Tarceva [erlotinib]
Date of Report: To be Published
Phase: IV
-
Protocol Number: ML25575
Product Name: Tarceva [erlotinib]
Date of Report: To be Published
Phase: IV
-
Protocol Number: ML25434
Product Name: Tarceva [erlotinib]
Date of Report: To be Published
Phase: II
-
Protocol Number: ML25423
Product Name: Tarceva [erlotinib]
Date of Report: To be Published
Phase: II
-
Protocol Number: ML17915
Product Name: erlotinib
Date of Report: To be Published
Phase: II
-
Protocol Number: MO22201
Product Name: erlotinib
Date of Report: To be Published
Phase: III
-
Protocol Number: MO22162
Product Name: Tarceva [erlotinib]
Date of Report: To be Published
Phase: III
-
Protocol Number: YO25121
Product Name: Tarceva [erlotinib]
Date of Report: To be Published
Phase: III
-
Protocol Number: NO21160
Product Name: RG1507
Date of Report: To be Published
Phase: II
-
Protocol Number: GDC4626g
Product Name: GDC-0941
Date of Report: To be Published
Phase: I
-
Protocol Number: GDC4628g
Product Name: GDC-0941
Date of Report: To be Published
Phase: I
-
Protocol Number: ML21450
Product Name: erlotinib
Date of Report: To be Published
Phase: III
-
Protocol Number: ML25200
Product Name: Tarceva [erlotinib]
Date of Report: To be Published
Phase: II
-
Protocol Number: ML25279
Product Name: Tarceva [erlotinib]
Date of Report: To be Published
Phase: II
-
Protocol Number: MO18109
Product Name: erlotinib
Date of Report: To be Published
Phase: IV
-
Protocol Number: NP22383
Product Name: RO4929097
Date of Report: To be Published
Phase: II
-
Protocol Number: BO18602
Product Name: erlotinib [Tarceva] [erlotinib]
Date of Report: 01.12.2010
Phase: III
-
Protocol Number: ML22991
Product Name: Avastin [bevacizumab]
Date of Report: To be Published
Phase: IV
-
Protocol Number: ML25493
Product Name: Avastin [bevacizumab]
Date of Report: To be Published
Phase: IV
-
Protocol Number: ML23023
Product Name: Tarceva [erlotinib]
Date of Report: To be Published
Phase: IV
-
Protocol Number: ML27895
Product Name: Tarceva [erlotinib]
Date of Report: To be Published
Phase: IV
-
Protocol Number: ML28282
Product Name: Tarceva [erlotinib]
Date of Report: To be Published
Phase: IV
-
Protocol Number: ML22973
Product Name: Tarceva [erlotinib]
Date of Report: To be Published
Phase: IV
An Observational Study of Tarceva (Erlotinib) in Patients With Non-Small Cell Lung Cancer
-
Protocol Number: ML27773
Product Name: Tarceva [erlotinib]
Date of Report: To be Published
Phase: IV
-
Protocol Number: ML21474
Product Name: Tarceva [erlotinib]
Date of Report: To be Published
Phase: IV
-
Protocol Number: ML22816
Product Name: Tarceva [erlotinib]
Date of Report: To be Published
Phase: IV
-
Protocol Number: ML25708
Product Name: Tarceva [erlotinib]
Date of Report: To be Published
Phase: IV
-
Protocol Number: ML25494
Product Name: Avastin [bevacizumab]
Date of Report: To be Published
Phase: IV
-
Protocol Number: ML22485
Product Name: erlotinib [Tarceva] [erlotinib]
Date of Report: 28.06.2012
Phase: II
-
Protocol Number: ML27860
Product Name: Tarceva [erlotinib]
Date of Report: To be Published
Phase: III
-
Protocol Number: NO21746
Product Name: RG1507 [RG1507]
Date of Report: 01.12.2010
Phase: II
-
Protocol Number: ML20773
Product Name: erlotinib [Tarceva] [erlotinib]
Date of Report: 04.01.2011
Phase: II
-
Protocol Number: ML28361
Product Name: Tarceva [erlotinib]
Date of Report: To be Published
Phase: IV
-
Protocol Number: ML28306
Product Name: Avastin [bevacizumab]
Date of Report: To be Published
Phase: IV
-
Protocol Number: ML21150
Product Name: Avastin [bevacizumab [Avastin]]
Date of Report:
Phase: II
-
Protocol Number: ML21308
Product Name: erlotinib [Tarceva] [erlotinib]
Date of Report: 25.01.2010
Phase: II
-
Protocol Number: MO19390
Product Name: Avastin [bevacizumab [Avastin]]
Date of Report: 01.07.2010
Phase: IV
-
Protocol Number: MO22089
Product Name: Avastin [bevacizumab [Avastin]]
Date of Report: 30.04.2012
Phase: III
-
Protocol Number: ML28195
Product Name: Tarceva [erlotinib]
Date of Report: To be Published
Phase: IV
-
Protocol Number: WO20024
Product Name: pertuzumab [pertuzumab]
Date of Report: 01.06.2009
Phase: I
-
Protocol Number: DNB4987g
Product Name: DNIB0600A
Date of Report: To be Published
Phase: I
-
Protocol Number: GO27912
Product Name: GDC-0941
Date of Report: To be Published
Phase: II
-
Protocol Number: MEF4984g
Product Name: MEGF0444A
Date of Report: To be Published
Phase: II
-
Protocol Number: ML20569
Product Name: Tarceva [erlotinib [Tarceva]]
Date of Report: 29.06.2011
Phase: IV
Study of Tarceva (Erlotinib) in patients withadvanced stage non-small cell lung cancer
About This Database
This database is populated with information on the results of Roche-sponsored clinical trials.